Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab dose optimization in rheumatoid arthritis
NL-OMON60722Phase 4Recruiting
- Sponsor
- Reade
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Reade. Started Jan 2025; status: recruiting.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON60722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60722.